Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
NCT05564117
Completed
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Univsty Of AL At Birmingham, Birmingham, Alabama +21 locations
Conditions: Overweight, Obesity
Register for Updates
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
NCT06934655
Not Yet Recruiting
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary out... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
04/11/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
Register for Updates
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
NCT05371496
Enrolling By Invitation
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Register for Updates
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
NCT05548647
Active Not Recruiting
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania
Conditions: Obesity
Register for Updates
Feasibility of Semaglutide in Advanced Lung Disease
NCT05746039
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Register for Updates
Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo
NCT06577090
Active Not Recruiting
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2025
Locations: Pinnacle Research Group, Anniston, Alabama +15 locations
Conditions: Obesity
Register for Updates
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
NCT06575738
Recruiting
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
02/24/2025
Locations: Childrens Hospital Colorado, Aurora, Colorado
Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
Register for Updates
A Study of a Novel Precision Medicine Approach for Obesity
NCT06814938
Recruiting
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations
Conditions: Obesity
Register for Updates
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
NCT06388187
Active Not Recruiting
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Aurora FDRC Inc., Costa Mesa, California +23 locations
Conditions: Obesity
Register for Updates
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
NCT06533527
Recruiting
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hos... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2025
Locations: Cleveland Clinic, Weston, Florida +1 locations
Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Register for Updates
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
NCT04788511
Completed
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +92 locations
Conditions: Obesity
Register for Updates